WEBULL
WebtradeDownload

Arcus Biosciences Stock Misses Revenue as Kidney Cancer Trial Readout Nears

Simply Wall St · 2d ago
  • Arcus Biosciences reported third quarter 2026 revenue of US$9 million and a net loss of US$128 million, with basic loss per share from continuing operations of US$1, alongside a wider nine month loss and sharply lower year to date revenue versus the prior period.
  • The update on casdatifan showed Arcus Biosciences moving toward completion of the PEAK-1 Phase 3 kidney cancer trial and planning the PEAK-20 first line study, with management indicating a long cash runway to continue funding this concentrated development effort.
  • We will now look at how Arcus Biosciences' investment narrative is influenced by the wider loss and casdatifan trial progress.

Scan beyond Arcus Biosciences by reviewing hand picked peers with resilient balance sheets and cleaner fundamentals in our list of solid balance sheet and fundamentals (24 results).

Arcus Biosciences Investment Narrative Recap

To own Arcus Biosciences, you need to believe the casdatifan kidney cancer program can eventually support a commercial franchise large enough to offset years of heavy R&D spend. The latest update, with revenue at US$9 million and a quarterly net loss of US$128 million, underlines how dependent the story is on trial execution rather than current sales.

The key short term catalyst remains clinical and regulatory progress for casdatifan, especially the Phase 3 PEAK trials. The risk side is equally clear. Ongoing losses, the widened nine month deficit and the toxicity profile of casdatifan keep funding needs, real world uptake and regulatory timing firmly in focus.

The most relevant update for this earnings print is management’s confirmation that enrollment in PEAK-1, the Phase 3 casdatifan plus cabozantinib trial in second line kidney cancer, is close to completion. This keeps the operational spotlight on whether Arcus Biosciences can deliver clean data from a pivotal program while managing anemia and hypoxia seen with the drug.

Plans to start the PEAK-20 first line study by the end of 2026, together with a cash runway guided into 2029, help explain why investors watch quarterly losses differently here than in a mature business. Your assessment comes down to execution on these casdatifan milestones versus the ongoing risk of trial delays, safety concerns or future dilution.

Arcus Biosciences' narrative anchors on analysts projecting US$263.5 million in revenue and US$48.2 million in earnings by 2029. This sits alongside an assumed 31.1% yearly revenue growth rate and an earnings swing of about US$508.2 million from earnings today of a US$460.0 million loss to the forecast consensus earnings level.

Uncover why Arcus Biosciences' fair value indicates a 132% potential upside to its current price that could narrow quickly.

NYSE:RCUS 1-Year Stock Price Chart
NYSE:RCUS 1-Year Stock Price Chart

Exploring Other Perspectives

For a very different angle, some of the most optimistic analysts focus less on near term earnings misses and more on casdatifan as a possible backbone therapy. Before this update, that group was working with revenue closer to US$1.1b and earnings of about US$167.1 million by 2029, so today’s results may challenge or reinforce those expectations.

Explore 2 other Arcus Biosciences fair value estimates, including one that suggests up to 138% upside from the current price.

Reach Your Own Conclusion

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Investment Ideas Beyond Arcus Biosciences?

If the Arcus Biosciences story has sharpened your thinking about risk, reward and balance sheets, it can be useful to line it up against other opportunities that share some of the qualities you care about most. The Simply Wall St Screener can help you quickly surface stocks that match different priorities so you can pressure test your thesis and avoid anchoring on a single company.